The European Medicines Agency sets a "decision date" for the fate of the "Pfizer / Biontech" vaccine

The European Medicines Agency announced today, Tuesday, that it will hold an extraordinary meeting on December 29 as a "deadline" to consider an urgent approval to market a vaccine against Covid-19 developed by German Biontech and the US giant Pfizer.

The regulatory agency said in a statement, "In the event that the data provided are robust enough to reach conclusions about the quality and safety of the vaccine, the European Medicines Agency will complete its study during an exceptional meeting scheduled for December 29 as a deadline."

Pfizer and Biontec had announced earlier that they had applied for conditional approval from the European Union for their vaccine, following a similar request in the United States.

Follow our latest local and sports news, and the latest political and economic developments via Google news